AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18385980 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐ONE PEMFs treatment (active group)
Number of subjects: 69
Study 18385980 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 69
Study 16441988 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (incision-curettage)
Number of subjects: 141
Study 16441988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection
Number of subjects: 141
Study 12596079 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stent implantation (DS)
Number of subjects: 250
Study 12596079 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting (PB)
Number of subjects: 250
Study 11111356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-guided counseling (PGC) with written prompt for questions
Number of subjects: 0
Study 11111356 — intervention group
Group type: EXPERIMENTAL
Intervention: Written prompt encouraging questions followed by customary verbal counseling
Number of subjects: 0
Study 11111356 — intervention group
Group type: COMPARATOR
Intervention: Control group with customary verbal counseling and no prompts
Number of subjects: 0
Study 9085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations to discontinue intravenous antibiotic therapy
Number of subjects: 102
Study 9085319 — intervention group
Group type: COMPARATOR
Intervention: Observation without intervention
Number of subjects: 102
Study 1490755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E (300 mg/day) for eight weeks
Number of subjects: 24
Study 1490755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2932213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose medroxyprogesterone acetate (HD-MPA) 400 mg daily
Number of subjects: 87
Study 2932213 — intervention group
Group type: COMPARATOR
Intervention: Mepitiostane (MS) 10 mg daily
Number of subjects: 87
Study 2932213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose medroxyprogesterone acetate (HD-MPA)
Number of subjects: 87
Study 2932213 — intervention group
Group type: COMPARATOR
Intervention: Mepitiostane (MS)
Number of subjects: 87
Study 31478240 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement error correction using external calibration sample
Number of subjects: 0
Study 31478240 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement error ignored
Number of subjects: 0
Study 31478240 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement error systematic or differential
Number of subjects: 0
Study 29474851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning (math n=10; spelling n=9)
Number of subjects: 2716
Study 29474851 — intervention group
Group type: COMPARATOR
Intervention: Traditional, sedentary academic lessons (n=9)
Number of subjects: 2716
Study 29474851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning with planned physical activity (PA)
Number of subjects: 2716
Study 29474851 — intervention group
Group type: COMPARATOR
Intervention: Greater dose of PA in control schools
Number of subjects: 2716
Study 27185509 — intervention group
Group type: EXPERIMENTAL
Intervention: Telekit system
Number of subjects: 60
Study 25509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sanyinjiao (SP 6), Hegu (LI 4), Qihai (CV 6), Guanyuan (CV 4), started 2 hours after operation, once a day for five days
Number of subjects: 70
Study 25509737 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment after cesarean section
Number of subjects: 70
Study 21811855 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion group (knee flexed to 30°)
Number of subjects: 110
Study 21811855 — intervention group
Group type: COMPARATOR
Intervention: Extension group (knee extended fully)
Number of subjects: 110
Study 20220185 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprotirome 25 microg per day
Number of subjects: 0
Study 20220185 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprotirome 50 microg per day
Number of subjects: 0
Study 20220185 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprotirome 100 microg per day
Number of subjects: 0
Study 20220185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18813048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure injection (> 20 psi)
Number of subjects: 80
Study 18813048 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure injection (< 15 psi)
Number of subjects: 80
Study 16041965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (CRP) for 12 weeks, 3 times a week
Number of subjects: 203
Study 16041965 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiology follow-up
Number of subjects: 203
Study 16041965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (CRP)
Number of subjects: 203
Study 11804979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lytic monotherapy
Number of subjects: 221
Study 11804979 — intervention group
Group type: COMPARATOR
Intervention: Lytic plus rhuMAb CD18
Number of subjects: 221
Study 10029609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine tablets, 4 g
Number of subjects: 94
Study 10029609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine microgranular preparation, 4 g
Number of subjects: 94
Study 10029609 — intervention group
Group type: COMPARATOR
Intervention: 6‐methylprednisolone, 40 mg
Number of subjects: 94
Study 7548602 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 0
Study 7548602 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus tobramycin
Number of subjects: 0
Study 7548602 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 0
Study 7548602 — intervention group
Group type: COMPARATOR
Intervention: Imipenem and cilastatin
Number of subjects: 0
Study 2208536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine + Metoclopramide + Sodium Citrate
Number of subjects: 196
Study 2208536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Number of subjects: 196
Study 2208536 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 196
Study 2208536 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 196
Study 7127178 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypotension during spinal fusion surgery
Number of subjects: 24
Study 7127178 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of somatosensory evoked potentials
Number of subjects: 24
Study 7127178 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal of hypotension and haemodilution when evoked potentials altered
Number of subjects: 24
Study 31018616 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 137
Study 29017578 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 181
Study 29017578 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study 25106663 — intervention group
Group type: EXPERIMENTAL
Intervention: Filorexant 10 mg nightly
Number of subjects: 235
Study 25106663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 24366758 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus S-1
Number of subjects: 639
Study 24366758 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 639
Study 22956052 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group (rosuvastatin 10 mg per day for 6 months)
Number of subjects: 70
Study 22956052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 22956052 — intervention group
Group type: COMPARATOR
Intervention: Statin group vs Control group
Number of subjects: 70
Study 19747406 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR ICG one hour after admission to the ICU
Number of subjects: 60
Study 19747406 — intervention group
Group type: EXPERIMENTAL
Intervention: Late postoperative ASAT measurement
Number of subjects: 60
Study 19747406 — intervention group
Group type: COMPARATOR
Intervention: PDR ICG, ASAT, and alpha-GST measurements
Number of subjects: 60
Study 17261626 — intervention group
Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) 50 to 600 mg with 100 mg ritonavir (RTV) every 12 hours or every 24 hours for 15 days
Number of subjects: 68
Study 17261626 — intervention group
Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) 800 mg every 12 hours for 15 days
Number of subjects: 68
Study 17261626 — intervention group
Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) with RTV 100 mg
Number of subjects: 68
Study 15578510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 800 mg/day for 24 weeks
Number of subjects: 491
Study 15578510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 800 mg/day for 48 weeks
Number of subjects: 491
Study 15578510 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 491
Study 15578510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin for 24 weeks in patients with HCV genotype 1
Number of subjects: 491
Study 15578510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin for 48 weeks in patients with HCV genotype 1
Number of subjects: 491
Study 15578510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin for 24 weeks in patients with HCV genotypes 2 or 3
Number of subjects: 491
Study 15578510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin for 48 weeks in patients with HCV genotypes 2 or 3
Number of subjects: 491
Study 11553111 — intervention group
Group type: COMPARATOR
Intervention: 0.376% sodium fluoride (1700 ppm fluoride ion)
Number of subjects: 5439
Study 11553111 — intervention group
Group type: COMPARATOR
Intervention: 0.486% sodium fluoride (2200 ppm fluoride ion)
Number of subjects: 5439
Study 11553111 — intervention group
Group type: COMPARATOR
Intervention: 0.619% sodium fluoride (2800 ppm fluoride ion)
Number of subjects: 5439
Study 11553111 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride (1100 ppm fluoride ion)
Number of subjects: 5439
Study 9474236 — intervention group
Group type: EXPERIMENTAL
Intervention: TICE® BCG (six weekly intravesical instillations)
Number of subjects: 30
Study 9474236 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 7892398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tridimensional Personality Questionnaire
Number of subjects: 0
Study 3048951 — intervention group
Group type: EXPERIMENTAL
Intervention: RAES (Ruscus aculeatus extract 16.5 mg, hesperidin 75 mg, ascorbic acid 50 mg), 2 capsules, 3 times/day for 2 months
Number of subjects: 40
Study 3048951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30779849 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEs-Intervention (ACEs-I)
Number of subjects: 54
Study 30779849 — intervention group
Group type: EXPERIMENTAL
Intervention: Activators
Number of subjects: 54
Study 30779849 — intervention group
Group type: COMPARATOR
Intervention: ACEs-Control (ACEs-C)
Number of subjects: 54
Study 28866110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikram yoga (3-5 classes per week for 16 weeks)
Number of subjects: 63
Study 27664367 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM) training
Number of subjects: 40
Study 27664367 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control (PC)
Number of subjects: 40
Study 25687152 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based sleep education program
Number of subjects: 3713
Study 25687152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sleep program)
Number of subjects: 3713
Study 23299384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2 fish oil capsules per day for 6 months)
Number of subjects: 126
Study 23299384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 olive oil capsules per day for 6 months)
Number of subjects: 126
Study 19760131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal dartos flap (Group 1, mean age 22.3 years)
Number of subjects: 42
Study 19760131 — intervention group
Group type: COMPARATOR
Intervention: Ventral dartos flap (Group 2, mean age 21.1 years)
Number of subjects: 42
Study 19057251 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-door cervical laminoplasty using suture anchors
Number of subjects: 145
Study 17140047 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of rectal indomethacin administered 2 hours prior to ERCP
Number of subjects: 117
Study 17140047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycerine suppository)
Number of subjects: 117
Study 14614780 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 500 mg
Number of subjects: 68
Study 14614780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10674604 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple anti-helicobacter therapy
Number of subjects: 99
Study 10674604 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 99
Study 9058216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS), 1 g IV before CPB
Number of subjects: 40
Study 9058216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin-full-dose protocol
Number of subjects: 40
Study 9058216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 8362629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation
Number of subjects: 51
Study 2946016 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (n = 17)
Number of subjects: 54
Study 2946016 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (low intensity transcutaneous nerve stimulation, n = 18)
Number of subjects: 54
Study 2946016 — intervention group
Group type: COMPARATOR
Intervention: TENS dead-battery (placebo, n = 18)
Number of subjects: 54
Study 2946016 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect (all groups)
Number of subjects: 54
Study 2946016 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale measure of average pain (Electroacupuncture group)
Number of subjects: 54
Study 31360884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 4830
Study 31360884 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 4830
Study 26669813 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight (HW) intervention
Number of subjects: 0
Study 26669813 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 0
Study 26669813 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study 25017182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20‐mg tablet
Number of subjects: 36
Study 25017182 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40‐mg tablet
Number of subjects: 36
Study 25017182 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin 20‐mg tablet and olmesartan 40‐mg tablet
Number of subjects: 36
Study 25017182 — intervention group
Group type: COMPARATOR
Intervention: Control (Mono-administration of rosuvastatin or olmesartan)
Number of subjects: 36
Study 22251033 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message reminders
Number of subjects: 206
Study 22251033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 206
Study 19875337 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy alone (n=233)
Number of subjects: 966
Study 19875337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with two courses of chemotherapy given simultaneously (SIM alone; n=166)
Number of subjects: 966
Study 19875337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy given after treatment (SUB alone; n=160)
Number of subjects: 966
Study 19875337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concurrent and maintenance chemotherapy (SIM+SUB; n=154)
Number of subjects: 966
Study 19875337 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (for patients who had undergone surgery; n=135)
Number of subjects: 966
Study 19875337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy (SIM alone; n=118)
Number of subjects: 966
Study 19134067 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme designed to account for training needs and learning styles
Number of subjects: 0
Study 19134067 — intervention group
Group type: COMPARATOR
Intervention: Standardised educational programme
Number of subjects: 0
Study 15672051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon treatment
Number of subjects: 43
Study 15672051 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 43
Study 15672051 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment followed by balloon treatment
Number of subjects: 43
Study 15672051 — intervention group
Group type: COMPARATOR
Intervention: Sham/balloon treated group
Number of subjects: 43
Study 15672051 — intervention group
Group type: COMPARATOR
Intervention: Balloon/balloon treated group
Number of subjects: 43
Study 12737679 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 10464894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education and supervision for self-management
Number of subjects: 162
Study 10464894 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 162
Study 8934371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy
Number of subjects: 0
Study 8934371 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine in hypertension studies
Number of subjects: 0
Study 1922667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (Nimotop)
Number of subjects: 50
Study 1922667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given Nimodipine)
Number of subjects: 50
Study 6225808 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of aztreonam
Number of subjects: 112
Study 6225808 — intervention group
Group type: COMPARATOR
Intervention: 2 g of spectinomycin
Number of subjects: 112
Study 31837710 — intervention group
Group type: EXPERIMENTAL
Intervention: Doming test using a custom doming dynamometer (standing)
Number of subjects: 40
Study 31837710 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe flexion tests using a custom toe flexion dynamometer (seated)
Number of subjects: 40
Study 31837710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure mat tests (standing)
Number of subjects: 40
Study 30899949 — intervention group
Group type: EXPERIMENTAL
Intervention: warm gutta‐percha filling technique + iRoot SP
Number of subjects: 95
Study 30899949 — intervention group
Group type: EXPERIMENTAL
Intervention: warm gutta‐percha filling technique + AH plus
Number of subjects: 95
Study 30899949 — intervention group
Group type: COMPARATOR
Intervention: warm gutta‐percha filling technique + Vitapex
Number of subjects: 95
Study 26555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment
Number of subjects: 319
Study 26555827 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 319
Study 26555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment and Observation (crossover patients)
Number of subjects: 319
Study 26555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment and Observation (patients with Cobb angles ≥ 40 degrees)
Number of subjects: 319
Study 24783988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice daily
Number of subjects: 426
Study 24783988 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with lopinavir 400 mg and ritonavir 100 mg twice daily plus lamivudine or emtricitabine and another NRTI
Number of subjects: 426
Study 24783988 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 426
Study 24783988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 426
Study 22178482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 0
Study 22178482 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (Control)
Number of subjects: 0
Study 19643627 — intervention group
Group type: EXPERIMENTAL
Intervention: Milking of chest tubes
Number of subjects: 145
Study 19643627 — intervention group
Group type: COMPARATOR
Intervention: Observation of chest tubes without manipulation
Number of subjects: 145
Study 17556901 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 or 40 mg)
Number of subjects: 0
Study 17556901 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg)
Number of subjects: 0
Study 17556901 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (10 or 20 mg)
Number of subjects: 0
Study 17556901 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 0
Study 15043959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1.2 g/m2)
Number of subjects: 552
Study 15043959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 11964587 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 34
Study 11964587 — intervention group
Group type: COMPARATOR
Intervention: Control (Oxygen mask)
Number of subjects: 34
Study 11964587 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP (air breathing)
Number of subjects: 34
Study 11964587 — intervention group
Group type: COMPARATOR
Intervention: Control (Oxygen mask, air breathing)
Number of subjects: 34
Study 11964587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 34
Study 10184835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 150 mg/day)
Number of subjects: 231
Study 10184835 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 to 60 mg/day)
Number of subjects: 231
Study 10184835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 231